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Metal carbonyls supported on iron oxide nanoparticles
to trigger the CO-gasotransmitter release by magnetic
heating†
Peter C. Kunz,*a Hajo Meyer,a Juri Barthel,b Silvio Sollazzo,c Annette M. Schmidt*c
and Christoph Janiak*a
Magnetic iron oxide, maghemite (Fe2O3) nanoparticles with covalent
surface-bound CO-releasing molecules (CORMs) can be triggered to
release CO through heating in an alternating magnetic field. In the
proof-of-concept study the rate of CO-release from [RuCl(CO3)-
(l-DOPA)]@maghemite nanoparticles was doubled upon exposure
to an external alternating magnetic field (31.7 kAm1, 247 kHz,
25 8C, 39.9 mTesla, DOPA = dioxyphenyl-alaninato).
Small gaseous molecules, so-called gasotransmitters, represent
important signal molecules in biological systems. Much research
has already been devoted to the multiple biological functions of
nitrogen monoxide (NO),1 so the signal-transfer properties of
carbonmonoxide (CO) and hydrogen sulfide (H2S) are now gaining
attention.2–4 The discovery of the cell regulating function of CO
was prevented for a long time by its known toxicity in medium and
higher doses. Carbon monoxide shows cell protective, anti-
inflammatory and vasodilatatory (blood vessel relaxing) effects which
confer it with great potential as a therapeutic agent.3 It is difficult to
correctly dose gaseous CO. Further, CO has a high affinity to
hemoglobin and cytochromes. This has prevented, so far, clinical
usage of CO despite its promising properties. The binding of CO to
hemoglobin and cytochromes endangers the oxygen supply upon
overdosage and is also responsible for its low bioavailability.4
The controlled dose-release of CO at the desired target tissue is
a major prerequisite for a meaningful therapeutic usage. The
utilization of CO-releasing molecules (CORMs, Scheme 1) is a
promising possibility for the release of defined amounts of CO
at the target tissue.5 The water soluble Ru-complex CORM-3
(Scheme 1) releases CO under physiological conditions and shows
vasodilatatoric, anti-inflammatory, renal protective, anti-ischemic
and anti-apoptotic effects in pre-clinical studies.6 The CO-release
is induced by a hydrolytic mechanism with pseudo-first order
kinetics and a half-life in the minute range.7 The physiologically
undefined and fast release limits the usage of CORM-3 consider-
ably. An important progress was the development of CORMs
which can be activated by an external stimulus (trigger) to release
CO. An example of such activable CORMs is the boranate carbo-
nate CORM-A1 which exhibits a pH-dependent CO-release.8 Also,
the photoinduced decarbonylation9 and enzymatic activation10 of
transition-metal complexes are mechanisms for activable systems.
Yet, the problem of spatially restricted release in the target tissue
still remains a challenge. A possible solution to this problem is the use
of nanoparticle carriers which allow both a controlled guidance to the
desired position as well as the time and spatially controlled release of
CO under local fields. Previous work has addressed the use of nano-
particular carriers for CORMs with spontaneous or photoinduced
CO-release.11 Here, we present the use of biocompatiblemagnetic iron
oxide nanoparticles (IONPs) as carriers for CORMs (CORM@IONP).
In a proof-of-concept study we demonstrate the triggered CO-release
through induced heating in an alternatingmagnetic field (Scheme 2).
Scheme 1 Examples of CO-releasingmolecules (CORMs) for biological investigations.
Scheme 2 Schematic presentation of induced CO-release from CORM-functionalized
iron oxide nanoparticles (IONP) through an alternating magnetic field.
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The heating of magnetic nanoparticles in alternating mag-
netic fields due to loss mechanisms (hyperthermia) has been
investigated for some years now for the thermo-ablation of
diseased tissue in cancer therapy.12 A macroscopic temperature
increase is possible with sufficient particle concentration in the
affected tissue. Furthermore, magnetic nanoparticles allow
for concentration in physiological environments by magnetic
control13 and can be used as transporters for the release of drug
compounds.14 Theoretical calculations suggest that a thermal
stationary state is quickly reached upon electromagnetic excita-
tion of nanoscopic (metallic or magnetic) particles due to their
high surface-to-volume-ratio. It is agreed that there is a negligible
temperature difference between the bulk phase of the particle and
its surrounding area. Depending on the particle size and the
surrounding medium an initiation time of about 100 ps can be
assumed.15 Experiments indicate that the energy transfer between
a particle and the surrounding phase leads to increased excitation
of vibrational degrees of freedom in the surface-bound molecules.
This can be used for the activation of release processes,14a,d
local phase transitions,14a,b targeted protein denaturation or
activation14c and oligonucleotide dehybridization.16
To test the concept of magnetic-nanoparticle heating for the
induced CO-release from supported CORMs, a suitable CORM-
compound was immobilized on the surface of maghemite
(Fe2O3) nanoparticles. First, the iron oxide particle surface
was functionalized with D/L-3-(3,4-dihydroxyphenyl)alanine
(D/L-DOPA) to provide an anchor group for the subsequent
introduction of the CORM-fragment. Product 2 (Scheme 3)
was collected using a magnet, washed and reacted in methanol
with [Ru2Cl4(CO)6] to yield CORM-functionalized nanoparticles
3 (Scheme 3). CORM@IONP, 3, contains a derivative of CORM-3
where the ruthenium carbonyl fragment carries a dioxyphenyl-
alaninato instead of a glycinato ligand. The former is applicable
in IONP surface immobilization through its dioxyphenyl or
catecholate unit. We intentionally chose a system which allows
for comparison with the well-investigated, fast CO-releaser
CORM-3 in order to have short kinetic measurements in the
investigation of this novel release concept. For additional control
experiments the molecular complex tri(carbonyl)-chlorido-
phenylalaninato-ruthenium(II) 4 was used.
Functionalization of the maghemite nanoparticles can be
followed using IR-spectroscopy (Fig. S3 in ESI†). The strong CO
stretching vibrations of the Ru(CO)3-fragment in 3 were
observed at around 2059 and 1986 cm1, which agree with
the vibrational frequencies of the analogous CORM-3 under
basic conditions (see also detailed IR description in ESI†).17
The maghemite NPs 1 have a hydrodynamic diameter of
(8  2) nm which increases to (11  3) nm for 2 after function-
alization with D/L-dihydroxyphenylalanine (both dynamic light
scattering, DLS, see ESI†). This value does not change through
reaction with [Ru2Cl4(CO)6] to give 3. The ligand-/CORM-shell
of 3 can be clearly seen in the high-resolution transmission
electron micrograph (TEM). Fig. 1b shows a representative
nanoparticle of 3 with its maghemite lattice planes along the
crystallographic [222] direction and the ligand corona. The
maghemite core diameter in 3 is (9  2) nm as shown by
TEM and the visible additional organic shell has a width of
around 2 nm which agrees very well with the value derived from
DLS for 2.
A Ru : Fe atom ratio of 1 : 25 was determined using ICP-MS,
that is, for each nanoparticle, there are about 400 Ru complexes
on the surface, corresponding to less than 60% of the estimated
possible coverage (see ESI†). The magnetic properties of nano-
particles 2 were determined using vibrating sample magneto-
metry (VSM). Lack of hysteresis shows superparamagnetic
behavior of the nanoparticles both in dispersion as well as in
the solid state. The saturation magnetization yields a high mass
fraction of the magnetic phase of about 67% (see Table S2,
ESI†) from which a volume-averaged core diameter of 12 nm is
calculated (see ESI,† Fig. S7, Table S2).
The CO-release was followed with a myoglobin assay using
UV/Vis-spectroscopy (see ESI†).18,19 For CORM@IONP 3 a single-
step pseudo-first order CO-release can be deduced without a
magnetic field from the relative decrease and increase in the
absorption at 541, 556 and 578 nm (Fig. 2 with Fig. S8 and S9,
ESI†). This observation is analogous to those for 4 (Fig. S12 in
ESI†) and CORM-3. Yet, the half-life for the CO-release from 3
with t1
2
= (13  2) min (25 1C) is much longer than those from 4
[t1
2
= (2.7  0.2) min, 20 1C] and CORM-3 (t1
2
= 2.3 min, 30 1C).19
This surface stabilization of the CORM towards solvolytic and
protein-reaction induced20 CO-release is explained by a diffu-
sion barrier in the surface layer and by steric hindrance from
the surrounding CORM molecules and free D/L-DOPA ligands.
A similar effect was described for a CORM in micelles.11c
Application of an external alternating magnetic field to
CORM@IONP 3 (31.7 kAm1, 247 kHz, 25 1C, 39.9 mTesla)
Scheme 3 Synthesis of CORM-functionalized nanoparticles 3 and the tri-
(carbonyl)-chlorido-phenylalaninato-ruthenium(II) model compound 4.
Fig. 1 TEM-images of CORM@IONP, 3. (a) Agglomerated (magnetic) nano-
particles, (b) a high-resolution image of one representative particle with lattice
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yields a two-fold accelerated CO-release rate with a half-life of
t1
2
= (7  2) min (Fig. 2, Table S3 in ESI†). It is important to note
that the temperature in the dispersion did not increase in the
thermostated cuvette during the application of the magnetic
field. Also, some deviation from a simple (pseudo-) first order
kinetic can be seen for the CO-release (Fig. S9 in ESI†). Future
studies shall elucidate this behavior. An enhanced CO-release
through excitation of the Ru(CO)3-fragment induced by an
alternating field can be excluded. The half-life values for CO
release from the phenylalaninato-model compound 4 without
and with an alternating magnetic field (no IONP present) were
identical [(2.7  0.2) min and (3.0  0.4) min] within
experimental error.
The observed rate increase shows the principal possibility
for a triggered (induced) CO-release in target tissue with the
nanoparticle nuclei acting as local field antennae. The acceler-
ated CO-release clearly shows the field-induced surface effect
(Scheme 2, Fig. 2 and Fig. S10, ESI†) despite the fast heat
dissipation and a low particle concentration which prevents a
macroscopic heating effect in the dispersion.
CORM-functionalized iron oxide nanoparticles have yielded a
new possibility of inducing a faster CO-release through an external
alternating magnetic field. Furthermore this concept which is
introduced here opens new ways to enrich tissue-specific CORMs,
by magnetic focusing or through attachment of additional tissue-
or cell-addressing ligands on the IONP surface.
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Notes and references
1 D. A. Riccio and M. H. Schoenfisch, Chem. Soc. Rev., 2012, 41,
3731–3741; A. W. Carpenter and M. H. Schoenfisch, Chem. Soc. Rev.,
2012, 41, 3742–3752; P. N. Coneski and M. H. Schoenfisch, Chem.
Soc. Rev., 2012, 41, 3753–3758.
2 A. K. Mustafa, M. M. Gadalla and S. H. Snyder, Sci. Signaling, 2009, 2, re2.
3 S. W. Ryter and L. E. Otterbein, BioEssays, 2004, 26, 270–280;
B. E. Mann, Organometallics, 2012, 31, 5728–5735; R. Motterlini,
B. Haas and R. Foresti, Med. Gas Res., 2012, 2, 28.
4 B. E. Mann, Topics in Organometallic Chemistry, Springer, Berlin,
Heidelberg, 2010.
5 C. C. Roma˜o, W. A. Bla¨ttler, J. D. Seixas and G. J. L. Bernardes, Chem.
Soc. Rev., 2012, 41, 3571–3583; T. Johnson, B. E. Mann, J. Clark,
R. Foresti and C. Green, Angew. Chem., Int. Ed., 2003, 42, 3722–3729.
6 R. Motterlini and L. E. Otterbein, Nat. Rev. Drug Discovery, 2010, 9,
728–743; R. Alberto and R. Motterlini, Dalton Trans., 2007, 1651–1660;
R. Motterlini, B. E. Mann, T. Johnson, J. Clark, R. Foresti and C. Green,
Curr. Pharm. Des., 2003, 9, 2525–2539.
7 R. Motterlini, B. E. Mann and R. Foresti, Expert Opin. Invest. Drugs,
2005, 14, 1305–1318.
8 R. Motterlini, P. Sawle, S. Bains, J. Hammad, R. Alberto, R. Foresti
and C. Green, FASEB J., 2005, 18, 284–286.
9 A. E. Pierri, A. Pallaoro, G. Wu and P. C. Ford, J. Am. Chem. Soc., 2012,
134, 18197–18200; W. Huber, R. Linder, J. Niesel, U. Schatzschneider,
B. Spingler and P. C. Kunz, Eur. J. Inorg. Chem., 2012, 3140; V. P. L.
Vela´squez, T. M. A. Jazzazi, A. Malassa, H. Gorls, G. Gessner, S. H.
Heinemann andM.Westerhausen, Eur. J. Inorg. Chem., 2012, 1072–1078;
D. Crespy, K. Landfester, U. S. Schubert and A. Schiller, Chem. Commun.,
2010, 46, 6651–6662; R. D. Rimmer, H. Richter and P. C. Ford, Inorg.
Chem., 2010, 49, 1180–1185; U. Schatzschneider, Eur. J. Inorg. Chem.,
2010, 1451–1467; P. C. Kunz, W. Huber, A. Rojas, U. Schatzschneider and
B. Spingler, Eur. J. Inorg. Chem., 2009, 5358–5366.
10 S. Romanski, B. Kraus, M. Guttentag, W. Schlundt, H. Ru¨cker,
A. Adler, J.-M. Neudoerfl, R. Alberto, S. Amslinger and H. G.
Schmalz, Dalton Trans., 2012, 41, 13862–13875.
11 (a) N. E. Bru¨ckmann, M. Wahl, G. J. Reiß, M. Kohns, W. Wa¨tjen and
P. C. Kunz, Eur. J. Inorg. Chem., 2011, 4571–4577; (b) G. Do¨rdelmann,
H. Pfeiffer, A. Birkner and U. Schatzschneider, Inorg. Chem., 2011, 50,
4362–4367; (c) U. Hasegawa, A. J. van der Vlies, E. Simeoni, C. Wandrey
and J. A. Hubbell, J. Am. Chem. Soc., 2010, 132, 18273–18280.
12 A. J. Cole, V. C. Yang and A. E. David, Trends Biotechnol., 2011, 29,
323–332.
13 A. S. Lu¨bbe, C. Alexiou and C. Bergemann, J. Surg. Res., 2001, 95,
200–206; C. Alexiou, W. Arnold, R. J. Klein, F. G. Parak, P. Hulin,
C. Bergemann, W. Erhardt, S. Wagenpfeil and A. S. Lu¨bbe, Cancer
Res., 2000, 60, 6641–6648.
14 (a) A. M. Schmidt, J. Magn. Magn. Mater., 2005, 289, 5–8;
(b) R. Messing and A. M. Schmidt, Prog. Colloid Polym. Sci., 2008,
134, 134–140; (c) T. Gelbrich, G. U. Marten and A. M. Schmidt,
Polymer, 2010, 51, 2818–2824; (d) G. U. Marten, T. Gelbrich and
A. M. Schmidt, Beilstein J. Org. Chem., 2010, 6, 922–931.
15 M. Perner, P. Bost, U. Lemmer, G. von Plessen, J. Feldmann,
U. Becker, M. Mennig, M. Schmitt and H. Schmidt, Phys. Rev. Lett.,
1997, 78, 2192; P. Keblinski, D. Cahill, A. R. Bodapati and T. A. Tato,
J. Appl. Phys., 2006, 100, 1–5; I. Levine, O. Shenkman, M. Winkler,
A. M. Schmidt and M. Gottlieb, Macromol. Symp., 2010, 291–292(1),
278–286.
16 J. Stehr, C. Hrelescu, R. Sperling, G. Raschke, M.Wunderlich, A. Nichtl,
D. Heindl, K. Ku¨rzinger, W. J. Parak, T. A. Klar and J. Feldmann,
Nano Lett., 2008, 8, 619–623; M. Reismann, J. C. Bretschneider,
G. von Plessen and U. Simon, Small, 2008, 4, 607–610.
17 T. R. Johnson, B. E. Mann, I. P. Teasdale, H. Adams, R. Foresti,
C. J. Green and R. Motterlini, Dalton Trans., 2007, 1500–1508.
18 A. J. Atkin, J. M. Lynam, B. E. Moulton, P. Sawle, R. Motterlini,
N. M. Boyle, M. T. Pryce and I. J. S. Fairlamb, Dalton Trans., 2011, 40,
5755–5761.
19 S. McLean, B. E. Mann and R. K. Poole, Anal. Biochem., 2012, 427,
36–40.
20 T. Santos-Silva, A. Mukhopadhyay, J. D. Seixas, G. J. L. Bernardes,
C. C. Roma˜o and M. J. Roma˜o, J. Am. Chem. Soc., 2011, 133, 1192–1195.
Fig. 2 (a) Typical change in the absorption bands of reduced skeletal muscle
horse myoglobin (76 mM) between 500–600 nm during the CO-release from
CORM@IONP 3, here with an alternating magnetic field (247 kHz, 31.7 kAm1,
39.9 mTesla) at 25 1C. Intensity changes were followed at 541, 556 and 578 nm
to give the typical CO-release curves in (b) from which the decrease in half-life
with a magnetic field can be quantified. Empty symbols (r), without a field; filled
symbols (m), with an alternating magnetic field; blue symbols ( , ), change in
the intensity at 541 nm; red-brown symbols ( , ), change in the intensity at
556 nm; green symbols ( , ), change in the intensity at 578 nm.
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